LabCorp 2012 Annual Report Download - page 53

Download and view the complete annual report

Please find page 53 of the 2012 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 54

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54

Corporate Headquarters
358 South Main Street
Burlington, NC 27215
336-584-5171
Information Sources
Information about LabCorp is available from
the following Company sources:
Investor Relations Contact
Stephen Anderson
Vice President, Investor Relations
336-436-5076
Center for Molecular Biology and Pathology
800-345-4363
Center for Occupational Testing
800-833-3984
Center for Esoteric Testing
800-334-5161
Paternity/Identity
800-762-4344
LabCorp Drug Development Laboratory
Services
877-788-8861
Web Site
www.labcorp.com
Transfer Agent
American Stock Transfer & Trust Company
Shareholder Services
6201 Fifteenth Avenue
Brooklyn, NY 11219
800-937-5449
www.amstock.com
Independent Registered
Public Accounting Firm
PricewaterhouseCoopers LLP
800 Green Valley Road, Suite 500
Greensboro, NC 27408
Annual Meeting
The annual meeting of shareholders will be
held at 9:00 a.m. EDT on May 8, 2013 at the
Paramount Theater, 128 East Front Street,
Burlington, NC 27215.
Form 10-K
Copies of Form 10-K as fi led with the Securities
and Exchange Commission are available without
cost to shareholders by writing to:
Laboratory Corporation of America Holdings
Investor Relations Department
358 South Main Street
Burlington, NC 27215
Safe Harbor
Forward-looking statements in this annual
report are subject to change based on various
important factors, including without limitation,
competitive actions in the marketplace and
adverse actions of governmental and other
third-party payers. Actual results could differ
materially from those suggested by these
forward-looking statements. Further information
on potential factors which could affect the
Company’s fi nancial results is included in the
Company’s Form 10-K for the year ended
December 31, 2012, and subsequent fi lings.
Common Stock
The Company's common stock, par value
$0.10 per share (the “Common Stock”), trades
on the New York Stock Exchange (“NYSE”)
under the symbol “LH.” The following table
sets forth for the calendar periods indicated
the high and low sales prices for the Common
Stock reported on the NYSE Composite Tape.
2012 2011
High Low High Low
1Q 93.30 85.58 92.98 86.19
2Q 94.33 81.56 100.94 92.09
3Q 95.30 83.50 99.76 76.91
4Q 94.30 82.15 88.15 74.57
Shareholder and Company Information
Corporate Governance, Code of Business Conduct and Ethics
– The Company’s Corporate Governance Guidelines, the Charters of its Audit Committee,
Compensation Committee, Quality and Compliance Committee, and Nominating and Corporate Governance Committee as well as the Company’s Code of
Business Conduct and Ethics are available on the Company’s Web Site at www.labcorp.com. You can also obtain a hard copy of these documents, without
charge, upon written request to Stephen Anderson, Laboratory Corporation of America Holdings, 358 South Main Street, Burlington, NC 27215.
BOARD OF DIRECTORS
David P. King
Chairman and Chief Executive Offi cer
Kerrii B. Anderson 1,2
Former Chief Executive Offi cer and
President of Wendy’s International, Inc.
Jean-Luc Bélingard 2,3
Chairman, bioMérieux S.A.;
retired Chairman and CEO, Ispen S.A.
N. Anthony Coles, M.D., MPH 3
President and Chief Executive Offi cer of
Onyx Pharmaceuticals, Inc.
Wendy E. Lane 1,4
Chairman of Lane Holdings, Inc.,
an investment fi rm
Thomas P. Mac Mahon 3,4
Former Chairman and Chief Executive Offi cer of
Laboratory Corporation of America Holdings
Robert E. Mittelstaedt, Jr. 1,4
Dean and Professor, W.P. Carey School
of Business, Arizona State University
Arthur H. Rubenstein, MBBCh 1,3
Professor of Medicine
University of Pennsylvania
Perelman School of Medicine
M. Keith Weikel, Ph.D. 2,3
Former Senior Executive Vice President and
Chief Operating Offi cer of HCR Manor Care, Inc.
R. Sanders Williams, M.D. 1,4
President of The J. David Gladstone Institutes
Committees:
1 Audit
2 Compensation
3 Quality and Compliance
4 Nominating and Corporate Governance
EXECUTIVE MANAGEMENT
David P. King, Chairman and
Chief Executive Offi cer
James T. Boyle, Executive Vice President,
Chief Operating Offi cer
William B. Hayes, Executive Vice President,
Chief Financial Offi cer
Mark E. Brecher, M.D., Senior Vice President,
Chief Medical Offi cer
F. Samuel Eberts III, Senior Vice President,
Chief Legal Offi cer
Adam T. Feinstein. Senior Vice President,
Corporate Development & Strategic Planning
Lidia L. Fonseca, Senior Vice President,
Chief Information Offi cer
Lisa Hoffman Starr, Senior Vice President,
Human Resources
LABORATORY CORPORATION OF AMERICA